Idera Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Idera Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Idera Pharmaceuticals: 10 sponsored US clinical trials, none currently recruiting.

Idera Pharmaceuticals sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 1 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Refractory Solid Tumors, with 1 trials.

Top-decile sponsor footprint

Idera Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

10 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

NCT03865082
TERMINATED Phase 3

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

NCT03445533
COMPLETED Phase 1

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

NCT03052205
COMPLETED Phase 2

A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma

NCT02644967
COMPLETED Phase 2

Trial of IMO-8400 in Adult Patients With Dermatomyositis

NCT02612857
COMPLETED Phase 1

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

NCT02252146
TERMINATED Phase 1

Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

NCT02092909
COMPLETED Phase 2

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

NCT01622348
COMPLETED Phase 1

Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients

NCT00728936
COMPLETED Phase 2

Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

NCT00729053

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5
Phase 3 1

Therapeutic Areas

Refractory Solid Tumors 1
Melanoma 1
Renal Cell Carcinoma 1
Solid Tumor 1

How the Idera Pharmaceuticals early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 7 completed (70%).

Phase mix: 1 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Refractory Solid Tumors (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Idera Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Idera Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Idera PharmaceuticalsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Idera Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Idera Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Idera Pharmaceuticals page

10 registered trials is a research-attention snapshot, not an endorsement of Idera Pharmaceuticals or any single study.

  • None of Idera Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Refractory Solid Tumors is the condition Idera Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Refractory Solid Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Idera Pharmaceuticals pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.